TGRX-326

TGRX-326 is a small-molecule drug developed by Shenzhen TargetRx. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: Subjects will be treated with the investigational drug TGRX-326 at 60 mg once day in 21-day cycles. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06082635 (TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)), in non-small-cell lung cancer. The largest, NCT06082635, plans to enrol 321 participants (actual) with primary completion expected 2026-04-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.